Lucitanib
Total Payments
$611,525
Transactions
154
Doctors
21
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $497,660 | 44 | 0 |
| 2019 | $113,865 | 110 | 21 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $568,347 | 48 | 92.9% |
| Consulting Fee | $31,500 | 21 | 5.2% |
| Travel and Lodging | $9,568 | 36 | 1.6% |
| Food and Beverage | $2,109 | 49 | 0.3% |
Payments by Type
Research
$568,347
48 transactions
General
$43,178
106 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | Clovis Oncology, Inc. | $522,574 | 0 |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | Clovis Oncology, Inc. | $45,773 | 0 |
Top Doctors Receiving Payments for Lucitanib
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Nashville, TN | $568,347 | 48 |
| , M.D | Obstetrics & Gynecology | Aurora, CO | $3,096 | 7 |
| , M.D | Gynecologic Oncology | Baltimore, MD | $2,756 | 8 |
| , MD | Medical Oncology | Boston, MA | $2,743 | 9 |
| Alexander Olawaiye | Gynecologic Oncology | Pittsburgh, PA | $2,717 | 8 |
| , MD | Gynecologic Oncology | Durham, NC | $2,676 | 8 |
| , MD | Gynecologic Oncology | Phoenix, AZ | $2,573 | 8 |
| , M.D | Gynecologic Oncology | New York, NY | $2,254 | 7 |
| , MD | Internal Medicine | Charlestown, MA | $2,251 | 7 |
| , MD | Obstetrics & Gynecology | Hilliard, OH | $2,112 | 7 |
| , M.D | Gynecologic Oncology | Birmingham, AL | $1,952 | 6 |
| , M.D | Gynecologic Oncology | Miami, FL | $1,928 | 5 |
| , M.D | Internal Medicine | New York, NY | $1,744 | 5 |
| , M.D. PH.D | Hematology & Oncology | Birmingham, AL | $1,710 | 5 |
| , MD | Medical Oncology | Dallas, TX | $1,613 | 2 |
| Rita Nanda | Hematology & Oncology | Burr Ridge, IL | $1,613 | 2 |
| , M.D., D.PHIL | Medical Oncology | New Haven, CT | $1,613 | 2 |
| , MD | Obstetrics & Gynecology | Indianapolis, IN | $1,613 | 2 |
| , MD | Hematology & Oncology | Houston, TX | $1,554 | 2 |
| , M.D | Hematology & Oncology | Durham, NC | $1,554 | 2 |
| , M.D., PH.D | Medical Oncology | Boston, MA | $1,554 | 2 |
| , MD | Medical Oncology | Nashville, TN | $1,554 | 2 |
Ad
Manufacturing Companies
- Clovis Oncology, Inc. $611,525
Product Information
- Type Drug
- Total Payments $611,525
- Total Doctors 21
- Transactions 154
About Lucitanib
Lucitanib is a drug associated with $611,525 in payments to 21 healthcare providers, recorded across 154 transactions in the CMS Open Payments database. The primary manufacturer is Clovis Oncology, Inc..
Payment data is available from 2019 to 2020. In 2020, $497,660 was paid across 44 transactions to 0 doctors.
The most common payment nature for Lucitanib is "Unspecified" ($568,347, 92.9% of total).
Lucitanib is associated with 2 research studies, including "A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor" ($522,574).